Trastuzumab/Hyaluronidase Drug Due Diligence Report 2026

This Trastuzumab/Hyaluronidase Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

1252

Registered trials

1239

Result records

194

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Trastuzumab/Hyaluronidase can convert its Monoclonal antibody, Enzyme profile and HER2 x Hyaluronic acid biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Trastuzumab/Hyaluronidase (query alias: Trastuzumab/Hyaluronidase)
Modality / target	Monoclonal antibody, Enzyme; HER2 x Hyaluronic acid; HER2 antagonists, Hyaluronic acid modulators, ADCC
Highest global status	Approved
Originator	Roche Holding AG
Active developers	Halozyme Therapeutics, Inc., Genentech, Inc.

The MCP disease footprint includes Breast Cancer, HER2 Positive Breast Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07695259	Phase 4	Recruiting	45	Pathological complete remission rate in breast cancer
ChiCTR2600128153	Phase 2	Not yet recruiting	70	Objective Response Rate (ORR)
NCT07694986	Phase 2	Recruiting	30	Safety Run-In: Maximum Tolerated Dose (MTD)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Clinical features of HER2-positive colorectal cancer: Real-world clinical practice

Not Applicable; n=26; evaluation: Positive. Reported fields: mPFS = 7.0 month ; mPFS = 5.0 month ; mPFS = 5.0 month

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, <i>ERBB2</i> -Positive Breast Cancer

Phase 2; n=98; evaluation: Positive. Reported fields: EFS(5-year) = 99.0 % ( 97 - 100)

Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial

Phase 3; n=766; evaluation: Positive. Reported fields: pCR = 64.1 % ( 59.1 - 69.0); pCR = 65.9 % ( 60.9 - 70.6)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Trastuzumab/Hyaluronidase addresses Breast Cancer, HER2 Positive Breast Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody, Enzyme—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 194 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: HER2 x Hyaluronic acid records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-07-14	Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy	Approved	US$600.0M upfront; US$900.0M milestones
2026-07-06	Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis	Preclinical	US$1,100.0M upfront; US$1,500.0M stated total
2026-06-09	GSK completes acquisition of Nuvalent, Inc.	NDA/BLA	US$10,600.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Subcutaneous her2 antibody formulations”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO